Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.67 |
| ▸ | MTOR | P42345 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.42 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.42 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.42 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclapolin 9 SCHEMBL31560145 | 1.00 | PLK1 (1.00) | PLK1CYP3A4CYP2C19CYP2C9CYP1A2 | |
| Hydroxyamine SCHEMBL6275415 | 0.89 | PLK1 (0.80) | PLK1CYP3A4CYP2C19CYP2C9CYP1A2 | |
| Cyclapolin 10 SCHEMBL5173340 | 0.87 | PLK1 (0.77) | PLK1CYP3A4CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL5172390 | 0.85 | PLK1 (0.74) | PLK1CYP3A4CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL5173548 | 0.83 | PLK1 (0.71) | PLK1CYP3A4CYP2C19CYP2C9CYP1A2 | |
| Cyclapolin 1 SCHEMBL5062617 | 0.82 | PLK1 (1.00) | PLK1CYP3A4CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL5169861 | 0.82 | PLK1 (0.69) | PLK1CYP3A4CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL5170233 | 0.82 | PLK1 (0.69) | PLK1CYP3A4CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL15253960 | 0.82 | PLK1 (0.69) | PLK1CYP3A4CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL5171055 | 0.82 | PLK1 (1.00) | PLK1CYP3A4CYP2C19CYP2C9CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250215101-A1 | DR5 Agonist and PLK1 Inhibitor or CDK Inhibitor Combination Therapy | INHIBRX BIOSCIENCES, INC. (US) | 2025-07-03 | — | — | US | claimed |
| EP-4504785-A1 | DR5 AGONIST AND PLK1 INHIBITOR OR CDK INHIBITOR COMBINATION THERAPY | Inhibrx Biosciences, Inc. (US) | 2025-02-12 | — | — | EP | claimed |
| WO-2023196943-A1 | DR5 AGONIST AND PLK1 INHIBITOR OR CDK INHIBITOR COMBINATION THERAPY | Inhibrx, Inc. (US) | 2023-10-12 | — | — | WO | claimed |
| EP-1589967-B1 | BENZTHIAZOLE-3 OXIDES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | CYCLACEL LTD (GB) | 2007-05-09 | — | — | EP | claimed |
| JP-2006518361-A | — | — | 2006-08-10 | — | — | JP | claimed |
| US-20060040997-A1 | Benzthiazole-3 oxides useful for the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2006-02-23 | — | — | US | claimed |
| EP-1589967-A1 | BENZTHIAZOLE-3 OXIDES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Cyclacel Limited (GB) | 2005-11-02 | — | — | EP | claimed |
| WO-2004067000-A1 | BENZTHIAZOLE-3 OXIDES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | CYCLACEL LIMITED (GB) | 2004-08-12 | — | — | WO | claimed |
| US-12545896-B2 | Growth inhibitor | Orizuru Therapeutics, Inc. (JP) | 2026-02-10 | — | — | US | disclosed |
| EP-3930839-B1 | ONVANSERTIB FOR INHIBITING NON-ADRENERGIC CONTRACTION OF SMOOTH MUSCLE AND PROSTATE CELL PROLIFERATION | CARDIFF ONCOLOGY INC (US) | 2026-01-28 | — | — | EP | disclosed |
| US-20250215101-A1 | DR5 Agonist and PLK1 Inhibitor or CDK Inhibitor Combination Therapy | INHIBRX BIOSCIENCES, INC. (US) | 2025-07-03 | — | — | US | disclosed |
| EP-4504785-A1 | DR5 AGONIST AND PLK1 INHIBITOR OR CDK INHIBITOR COMBINATION THERAPY | Inhibrx Biosciences, Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| EP-4479042-A1 | CANCER TREATMENT BY COMBINED INHIBITION OF POLO-LIKE KINASE AND MICROTUBULE POLYMERIZATION | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2024-12-25 | — | — | EP | disclosed |
| US-20240124846-A1 | GROWTH INHIBITOR | Orizuru Therapeutics, Inc. (JP) | 2024-04-18 | — | — | US | disclosed |
| EP-1589967-B1 | BENZTHIAZOLE-3 OXIDES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | CYCLACEL LTD (GB) | 2007-05-09 | — | — | EP | disclosed |
| EP-1683056-A2 | METHOD FOR IDENTIFYING INHIBITORS USING A HOMOLOGY MODEL OF POLO-LIKE KINASE 1 | Cyclacel Limited (GB) | 2006-07-26 | — | — | EP | disclosed |
| US-20060040997-A1 | Benzthiazole-3 oxides useful for the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2006-02-23 | — | — | US | disclosed |
| EP-1589967-A1 | BENZTHIAZOLE-3 OXIDES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Cyclacel Limited (GB) | 2005-11-02 | — | — | EP | disclosed |
| WO-2005047526-A2 | METHOD FOR IDENTIFYING INHIBITORS USING A HOMOLOGY MODEL OF POLO-LIKE KINASE 1 | CYCLACEL LIMITED (GB) | 2005-05-26 | — | — | WO | disclosed |
| WO-2004067000-A1 | BENZTHIAZOLE-3 OXIDES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | CYCLACEL LIMITED (GB) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040997-A1 | Benzthiazole-3 oxides useful for the treatment of proliferative disorders | CBR3, FGFR3, CCNH | PLK1 4291/4885CYP3A4 1540/4885CYP2C19 1942/4885 |
| US-12545896-B2 | Growth inhibitor | IAPP, PLK4, IGF1R | PLK1 62/4885CYP3A4 3461/4885CYP2C19 2694/4885 |
| US-20250215101-A1 | DR5 Agonist and PLK1 Inhibitor or CDK Inhibitor Combination Therapy | PLK1, BID, CDK11A | PLK1 1/4885CYP3A4 4407/4885CYP2C19 4595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.